Clovis Oncology (CLVS) Bounces Off Lows, Remains Down 13.8%
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Clovis Oncology (NASDAQ: CLVS) is bouncing off earlier lows as analysts at Piper Jaffray defend the name following this morning's data which was sub-par to a competitor's. Shares are up 13.8% after trading down nearly 30% earlier.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Acacia Communications (ACIA) Mentioned as Short in Lakewood Capital's Q3 Letter - Bloomberg
- Mercury Computer (MRCY) PT Raised to $30 at Jefferies Following 2Q Report
- Targa Resources (TRGP) PT Raised to $65 at Credit Suisse
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Trader Talk
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!